Identification of a novel major histocompatibility complex class II- restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells

Journal of Experimental Medicine

Volumn 189, Issue 10, 1999, Pages 1659-1667

  Wang, Rong Fu ^a   Wang, Xiang ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antitumor immunity; Chromosomal rearrangement; Fusion proteins; Immunotherapy; Melanoma antigens

Indexed keywords

CD4 ANTIGEN; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR1 ANTIGEN; HYBRID PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DNA SEQUENCE; FUSION GENE; HUMAN; HUMAN CELL; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA TRANSCRIPTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 19; CLONING, MOLECULAR; FUCOSYLTRANSFERASES; HLA-DR1 ANTIGEN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MOLECULAR SEQUENCE DATA; RECEPTORS, LDL; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0033577804     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.10.1659     Document Type: Article

References (38)

1. Boon, T., J.-C. Cerottini, B. Van Den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
2. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunol. Today. 18:175-182.
3. Wang, R.F. 1997. Tumor antigens discovery: perspectives for cancer therapy. Mol. Med. 3:716-731.
4. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, P.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4:321-327.
5. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6:722-727.
6. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588-594.
7. Kouskoff, V., A.S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:811-822.
8. Tisch, R., and H. McDevitt. 1996. Insulin-dependent diabetes mellitus. Cell. 85:291-297.
9. Bona, C.A., S. Casares, and T.D. Brumeanu. 1998. Towards development of T-cell vaccines, Immunol. Today. 19:126-133.
10. Riddell, S.R., and P.D. Greenberg. 1995. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:545-586.
11. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259-293.
12. Germain, R.N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 76:287-299.
13. Monach, P.A., S.C. Meredith, C.T. Siegel, and H. Schreiber. 1995. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2:45-59.
14. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965-1971.
15. Wang, R.-F., E. Appella, Y. Kawakami, X. Kang, and S.A. Rosenberg. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216.
16. Wang, R.-F., S.L. Johnston, G. Zeng, D.J. Schwartzentruber, and S.A. Rosenberg. 1998. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161:3596-3606.
17. Sanderson, S., K. Frauwirth, and N. Shastri. 1995. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Prof. Natl. Acad. Sci. USA. 92:7217-7221.
18. van Bergen, J., S.P. Schoenberger, F. Verreck, R. Amons, R. Offringa, and F. Koning. 1997. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc. Natl. Acad. Sci. USA. 94:7499-7502.
19. Fujii, S., S. Senju, Y.Z. Chen, M. Ando, S. Matsushita, and Y. Nishimura. 1998. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum. Immunol. 59:607-614.
20. Malcherek, G., C. Wirblich, N. Willcox, H.G. Rammensee, J. Trowsdale, and A. Melms. 1998. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur. J. Immunol. 28:1524-1533.
21. Wang, R.-F., X. Wang, A.C. Atwood, S.L. Topalian, and S.A. Rosenberg. 1999. Genetic approach to cloning genes encoding MHC class II-restricted antigens: mutated human CDC27 as a melanoma antigen. Science. In press.
22. Yamamoto, T., G.G. Davis, M.S. Brown, W.J. Schneider, M.L. Casey, J.L. Goldstein, and D.W. Russell. 1984. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 39:27-38.
23. Russell, D.W., W.J. Schneider, T. Yamamoto, K.L. Luskey, M.S. Brown, and J.L. Goldstein. 1984. Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. Cell. 37:577-585.
24. Koda, Y., M. Soejima, and H. Kimura. 1997. Structure and expression of H-type GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase gene (FUT1). Two transcription start sites and alternative splicing generate several forms of FUT1 mRNA J. Biol. Chem. 272:7501-7505.
25. Hobbs, H.H., M.S. Brown, and J.L. Goldstein. 1992. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1:445-466.
26. Rouquier, S., J.B. Lowe, R.J. Kelly, A.L. Fertitta, G.G. Lennon, and D. Giorgi. 1995. Molecular cloning of a human genomic region containing the H blood group alpha(1,2)fucosyltransferase gene and two H locus-related DNA restriction fragments. Isolation of a candidate for the human Secretor blood group locus. J. Biol. Chem. 270:4632-4639.
27. Rammensee, H.G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
28. Cheever, M.A., M.L. Disis, H. Bernhard, J.R. Gralow, S.L. Hand, E.S. Huseby, H.L. Qin, M. Takahashi, and W. Chen. 1995. Immunity to oncogenic proteins. Immunol. Rev. 145: 33-59.
29. Yotnda, P., F. Garcia, M. Peuchmaur, B. Grandchamp, M. Duval, F. Lemonnier, E. Vilmer, and P. Langlade-Demoyen. 1998. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102:455-462.
30. Lehrman, M.A., D.W. Russell, J.L. Goldstein, and M.S. Brown. 1987. Alu-Alu recombination deletes splice acceptor sites and produces secreted low density lipoprotein receptor in a subject with familial hypercholesterolemia. J. Biol. Chem. 262:3354-3361.
31. + T cells. J. Exp. Med. 189:757-766.
32. Tugendreich, S., J. Tomkiel, W. Earnshaw, and P. Hieter. 1995. CDC27Hs colocalizes with CDC16Hs to the centrosome and mitotic spindle and is essential for the metaphase to anaphase transition. Cell. 81:261-268.
33. King, R.W., J.M. Peters, S. Tugendreich, M. Rolfe, P. Hieter, and M.W. Kirschner. 1995. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell. 81:279-288.
34. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C.J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histo-compatibility complex class II negative tumors. J. Exp. Med. 187:693-702.
35. Kalams, S.A., and B.D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199-2204.
36. + T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
37. + T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 188:1883-1894.
38. + T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J. Exp. Med. 188:1875-1882.